Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBR5Q7)

Drug Name
Rolitetracycline Drug Info
Synonyms
Bristacin; Kinteto; Pyrrolidinomethyltetracycline; Reverin; Revrin; Rolitetraciclina; Rolitetracyclinum; Solvocillin; Superciclin; Synotodecin; Synterin; Syntetrex; Syntetrin; Tetraverin; Transcycline; Velacicline; Velacycline; AAT 4; SQ 15659; Pirrolidinometil-tetraciclina; Pirrolidinometil-tetraciclina [Italian]; Prm-TC; Rolitetraciclina [INN-Spanish]; Rolitetracyclinum [INN-Latin]; SQ 15,659; Synterin (TN); N-(Pyrrolidinomethyl)tetracycline; Pyrrolidino-methyl-tetracycline; N-Pyrrolidino-methyl-tetracycline; Rolitetracycline (JAN/USAN/INN); Rolitetracycline [USAN:INN:BAN:JAN]; N-(1-Pyrrolidinylmethyl)-tetracycline; (2Z,4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide
Therapeutic ClassAntibiotics
Cross-matching ID
PubChem CID
54682938
ChEBI ID
CHEMBL63334
CAS Number
CAS 751-97-3
TTD Drug ID
D05AFR

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Pyrimidine metabolism 1.96 0.00e+0 40/56 (71.43%) TYMS;RRM2;CTPS1;...
DNA replication 1.95 0.00e+0 34/36 (94.44%) PCNA;MCM6;RFC5;...
Thermogenesis 1.77 2.82e-2 173/232 (74.57%) PPARG;GNAS;ACSL1;...
Base excision repair 1.70 4.35e-2 29/33 (87.88%) PCNA;PARP2;FEN1;...
Bladder cancer -1.63 3.78e-2 40/41 (97.56%) E2F3;MMP1;RASSF1;...
mTOR signaling pathway -1.64 3.66e-2 114/154 (74.03%) TNF;WNT7A;RRAGD;...
Vibrio cholerae infection -1.64 3.43e-2 44/50 (88%) ATP6V0E1;ATP6V0A2;ATP6V1B2;...
Glycerolipid metabolism -1.65 3.18e-2 44/61 (72.13%) PNPLA3;ALDH9A1;ALDH7A1;...
Apoptosis -1.67 2.68e-2 126/168 (75%) SPTA1;ACTB;CTSL;...
Ubiquinone and other terpenoid-quinone biosynthesis -1.69 1.98e-2 9/11 (81.82%) VKORC1;NQO1;HPD
Tryptophan metabolism -1.70 1.94e-2 35/42 (83.33%) AOX1;KYAT3;CYP1A2;...
FoxO signaling pathway -1.70 1.83e-2 118/131 (90.08%) CCND1;INSR;GABARAPL1;...
Endometrial cancer -1.72 1.59e-2 56/58 (96.55%) ILK;GSK3B;BAD;...
Protein processing in endoplasmic reticulum -1.72 1.59e-2 127/171 (74.27%) NSFL1C;BCAP31;HSPBP1;...
IL-17 signaling pathway -1.72 1.53e-2 84/94 (89.36%) SRSF1;TAB2;IL1B;...
Insulin resistance -1.73 1.61e-2 96/108 (88.89%) INSR;PYGL;PRKAA1;...
Th17 cell differentiation -1.74 1.45e-2 95/107 (88.79%) STAT3;HLA-DOB;IL1B;...
Adipocytokine signaling pathway -1.75 1.28e-2 64/69 (92.75%) RXRG;POMC;PRKAA1;...
Pyruvate metabolism -1.76 1.27e-2 41/47 (87.23%) LDHB;ADH6;GLO1;...
Collecting duct acid secretion -1.77 1.26e-2 22/27 (81.48%) ATP6V0E1;ATP6V0A2;SLC4A1;...
TNF signaling pathway -1.78 1.35e-2 103/112 (91.96%) CREB3;IRF1;IFNB1;...
Alanine, aspartate and glutamate metabolism -1.83 5.59e-3 27/37 (72.97%) GFPT1;ALDH5A1;GAD2;...
Glycine, serine and threonine metabolism -1.84 4.85e-3 31/40 (77.5%) GCAT;AOC3;ALDH7A1;...
Arginine and proline metabolism -1.85 1.32e-3 39/50 (78%) PRODH2;ALDH9A1;ALDH7A1;...
Proximal tubule bicarbonate reclamation -1.85 1.45e-3 21/23 (91.3%) CA2;ATP1B2;GLUD2;...
Synaptic vesicle cycle -1.86 1.62e-3 63/78 (80.77%) AP2S1;STX2;ATP6V0E1;...
Arginine biosynthesis -1.88 1.82e-3 17/22 (77.27%) OTC;GLUD2;GOT1;...
Mitophagy -1.88 2.08e-3 56/68 (82.35%) CSNK2B;BNIP3;PINK1;...
Steroid biosynthesis -1.91 0.00e+0 19/20 (95%) SOAT1;HSD17B7;SQLE;...
Ferroptosis -1.92 0.00e+0 36/41 (87.8%) MAP1LC3B;FTH1;PRNP;...
Cysteine and methionine metabolism -1.98 0.00e+0 43/50 (86%) KYAT3;AHCY;ADI1;...
Biosynthesis of unsaturated fatty acids -2.04 0.00e+0 21/27 (77.78%) TECR;SCD;HSD17B4;...
Rheumatoid arthritis -2.19 0.00e+0 78/93 (83.87%) CXCL12;ATP6V0E1;ATP6V0A2;...
Mineral absorption -2.31 0.00e+0 48/60 (80%) STEAP1;FTH1;SLC5A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H